

INSURANCE COVERAGE APPEALS LETTER EXAMPLE TALKING POINTS

If Rasuvo® (methotrexate) injection coverage is denied by the patient's health plan, there may be varying levels of appeals. If you are uncertain about a plan's appeal levels or specific procedures, always refer to the plan's appeal guidelines. It is important to note that some plans may require a Letter of Medical Necessity to accompany the appeal.

Below is a list of potential talking points for healthcare providers (HCPs) to consider when appealing a coverage denial for Rasuvo for a patient. It is important to note that some plans may require a Letter of Medical Necessity to accompany the appeal.

The following is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. It is the responsibility of the HCP to ensure that all information provided regarding an individual patient is truthful and that all information relevant to the individual patient case is presented in such appeals. For Medicare beneficiaries, there are specific requirements that need to be met for the HCP to be considered a legal representative of the patient in an appeal. Providers are encouraged to contact third-party payers for specific information on their policies.

TALKING POINTS

- **Poor vision**—Poor vision can affect a patient's ability to safely see the marking on a small syringe, thus making it dangerous to inject scMTX at home. Misjudging one line on the syringe for another could result in under-dosing, which decreases efficacy, or over-dosing, which could lead to adverse reactions. Rasuvo is a prefilled auto-injector that delivers accurate dosing and removes the need for patients to manually prepare doses.
- **Lack of manual dexterity**—Lack of manual dexterity may affect the patient's ability to open oral medication containers and/or withdraw the correct dosage using a syringe and vial. Trouble handling the medication could limit a patient's ability to take their medication as prescribed. Rasuvo is a prefilled auto-injector that is delivered with the push of a button. It removes the need for patients to manually prepare doses and requires 50% fewer steps than syringe and vial.
- **Impaired cognitive ability to inject at home**—A patient's cognitive impairment could affect their ability to correctly prepare the medication. Rasuvo is a prefilled auto-injector that removes the need for patients to manually prepare doses and requires 50% fewer steps than syringe and vial.
- **Fear and/or aversion to needles**—Patients may experience anxiety when they see a needle. This fear of needles could prevent patients from adhering to their prescribed treatment. The Rasuvo auto-injector needle shield hides the needle from the patient's view.
- **Inadequate response to oral formulation**—Patients may not be receiving the optimal methotrexate dose because oral methotrexate has limited bioavailability and/or is associated with gastrointestinal side effects at higher doses. Subcutaneous administration of methotrexate could address these issues and could help patients avoid premature use of a costlier agent, such as a biologic.

USEFUL ICD CODES

M62.81	muscle weakness (generalized)
R29.898	other symptoms and signs involving the musculoskeletal system
F40.231	fear of injections and transfusions
H53.8	other visual disturbances
G31.84	mild cognitive impairment
Z91.13	patient's unintentional underdosing of medication regime
Z91.14	patient other non-compliance with medication regimen
Z91.19	patient's noncompliance with other medical treatment and regimen

Rasuvo (methotrexate autoinjector) has three indications: severe, active Rheumatoid Arthritis (RA), active polyarticular Juvenile Idiopathic Arthritis (pJIA) and severe, recalcitrant Psoriasis. To facilitate the prescribing of Rasuvo, the associated disease codes are listed below:

Rheumatoid Arthritis (RA)- M06.9
polyarticular Juvenile Idiopathic Arthritis (pJIA) - M08.00
Psoriasis - L40.9